New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 4, 2019 - The FDA announced the approval of Eli Lilly’s Emgality (galcanezumab-gnlm), for the treatment of episodic cluster headache in adults.
Download PDF
Return to publications
